A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

Clinical trial NCT07007793 · RECRUITING

Trial details

NCT number: NCT07007793
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Hyperaldosteronism

Start date: 2025-08-07
Primary completion: 2027-08-13
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.